The Star Ratings success of Medicare Advantage Part D (MAPD) plans working with seniors and the Low-Income Subsidy (LIS) program depends on how plans handle this special population. Here are the opportunities plans have to improve care and outcomes of LIS members.

Polypharmacy is a problem that belongs to all of us in the healthcare industry, which is why we need to address it together. If we want to really solve it, we’ll have to use analytics the way it was intended – leveraged as a powerful tool in a systematic approach.

There’s a grossly unaddressed problem in the industry for Medicare Advantage Part D (MAPD) plans. That problem is the ambiguous role of  “predictive analytics.” Well today, we’re throwing down the gauntlet and questioning the purpose and value of predictive analytics.

This week, our Vice President of Product Strategy and Management, gives Medicare Advantage Part D (MAPD) plans the low down on product implementation. Read on to get her tips on what to watch out for – and what to ask for – to ensure success with health tech partners as you gear up for new ways to beat cut points in 2019 and beyond.

If you’re a Medicare Advantage Part D (MAPD) health plan, your Star Ratings strategy can make or break you (and your bonus dollars). Here are some less obvious ways we see MAPD plans not meeting their Star Ratings potential.

Dr. Stephen Jones leads a team of analysts that brings diverse knowledge and expertise from all corners of healthcare. We asked Dr. Jones to shed a little light on how this collection of experts drives financial and quality results for national and regional health plan clients.

In the face of CMS’s proposed changes to everything from cut points to quality measures, Medicare Advantage Part D (MAPD) plans are asking themselves some hard questions about their 2020 Star Ratings programs. We asked Deborah O’Connor, RxAnte’s Director of Business Development, for the answers.